Meridian Bioscience, Inc. is a life science company doing business in (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturers.

According to the law firm press release, the Complaint alleges that throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Defendant’s lead tests provide inaccurate results; and (ii) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

On February 15, 2018, the Court issued an Order appointing Lead Plaintiff and Lead Counsel. Lead Plaintiff filed an amended Complaint on April 16. Defendants filed a Motion to Dismiss the amended Complaint on June 15. On February 13, 2019, the Court issued an Order granting Defendants' Motion to Dismiss the amended Complaint. The Court issued an Order granting Plaintiff's motion for reconsideration of the Dismissal Order on May 20. The Motion to Dismiss was denied in part.

On September 5, 2019, the parties entered into a Stipulation of Settlement. The Court issued an Order preliminarily approving the Settlement on October 9. On March 17, 2020, the Court granted final approval of the Settlement and entered Final Judgment. The Court issued an Order approving the Settlement's distribution plan on December 29.